Multi-System Inflammatory Syndrome in Children (MIS-C) Potentially Associated with COVID-19

Key Points:

- Several states are reporting cases compatible with multi-system inflammatory syndrome in children.
- At least three children in New York have died as of 5/10/2020.
- The syndrome appears to be characterized by persistent fever, severe inflammation, evidence of poor function in a single organ or many organs, and other specific clinical criteria and laboratory features, in the absence of other known infections. Some of these children have features that can be seen in Kawasaki disease, and some have clinical and laboratory signs of toxic shock syndrome.
- This inflammatory syndrome may occur days to weeks after acute COVID-19 illness. A majority of children have had virologic or serologic evidence of COVID-19 infection, but approximately one-third have not.
- Providers suspecting a case of MIS-C should perform both virologic and serological testing for SARS-CoV-2 RNA by PCR and antibodies by serology. Serum for SARS-CoV-2 antibodies should ideally be collected prior to the administration of intravenous immunoglobulin.
- Early recognition and specialist referral are essential, including to critical care if warranted. Cases frequently require intensive care unit admission for cardiac and/or respiratory support.

Immediately report any patient who meets the following criteria to the Alabama Department of Public Health using the Communicable Disease REPORT Card, and select Case of Public Health Importance.
Ivey to sign FY21 General Fund, ETF Budgets — Offers executive amendment on SB 161

Governor Kay Ivey on Thursday afternoon announced that she intends to sign both the Fiscal Year 2021 General Fund and Education Trust Fund budgets, however she has returned SB 161 — with an executive amendment tacked on — to the Senate. The executive amendment deals with federal coronavirus relief funds allocated to the State via the CARES Act. Ivey also penned a letter to the legislature explaining her latest moves. That letter can be read here.

The Race for Coronavirus Vaccines: Overview and Graphical Guide
More than 90 vaccines are being developed against SARS-CoV-2 by research teams in companies and universities across the world. Researchers are trialling different technologies, some of which haven’t been used in a licensed vaccine before. At least six groups have already begun injecting formulations into volunteers in safety trials; others have started testing in animals.

View the Graphical Guide Here
70% of Practices Severely Impacted by COVID-19 - What about Yours?

Please, take a few minutes and complete the survey right now. By doing so, you are helping better inform and shape the Medical Association’s advocacy efforts on COVID-19 related topics such as practice finance issues, loan and grant assistance programs, use of and experiences with telemedicine, and reimbursement issues.

Participate in the Survey Here.